810220 | C6-NBD Galactosyl Ceramide

N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-galactosyl-ß1-1'-sphingosine


Chloroform

Size SKU Packaging Price
250µg 810220C-250µg 810220C-250µg $983.00

Powder

Size SKU Packaging Price
250µg 810220P-250µg 810220P-250µg $983.00
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
Please select an option above.
${sku} - ${concentration}

C6-NBD Galactosyl Ceramide

C6-NBD Galactosyl Ceramide

N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-galactosyl-ß1-1'-sphingosine

Hygroscopic
Yes
Light Sensitive
Yes
Molecular Formula
C36H59N5O11
Percent Composition
C 58.60%, H 8.06%, N 9.49%, O 23.85%
Purity
>99%
Stability
1 Year
Storage Temperature
-20°C
CAS Number
170212-26-7
CAS Registry Number is a Registered Trademark of the American Chemical Society
Molecular Weight
737.881
Exact Mass
737.421
Ben-David, O., Y. Pewzner-Jung, O. Brenner, E.L. Laviad, A. Kogot-Levin, I. Weissberg, I.E. Biton, R. Pienik, E. Wang, S. Kelly, J. Alroy, A. Raas-Rothschild, A. Friedman, B. Brugger, A.H. Merrill Jr, and A.H. Futerman. (2011). Encephalopathy caused by ablation of very long acyl chain ceramide synthesis may be largely due to reduced galactosylceramide levels. J Biol Chem 286:30022-33. [PubMed]